Interleukin 2 News and Research

RSS

Microparticle-delivered therapy likely to be the first step toward stopping autoimmune diseases

According to the federal government's National Institute of Neurological Disorders and Stroke, nearly 3 million people worldwide -; with almost a third in the United States -; are living with multiple sclerosis (MS), a disabling neurological disease in which the body's immune system mistakenly attacks nerves feeding information to the central nervous system (the brain and spinal cord). Although rarely fatal, MS can lead to long-term disabilities, and impair movement, muscle control, vision and cognition.

6 Jun 2023

UCF researcher develops a new, more precise treatment for acute respiratory viral infections

A University of Central Florida College of Medicine researcher has developed a new, more precise treatment for a major cause of illness around the world each year -; acute respiratory viral infections.

9 May 2023

Tetravalent COVID vaccine provides broad antibody responses against SARS-CoV-2 variants in animal model

In a recent study posted to the bioRxiv* preprint server, researchers in Italy and the United States evaluated the efficacy and immunogenicity of an adjuvanted tetravalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein subunit 1 (S1) COVID-19 vaccine.

21 Mar 2023

Recent findings on T-cell immunity induced by SARS-CoV-2 infection and vaccination in immunocompromised individuals

Researchers discussed studies that explored T-cell immunity induced by SARS-CoV-2 infection and COVID-19 vaccination in cancer patients, individuals with HIV, and recipients of solid organ transplants.

8 Feb 2023

Recent therapeutic strategies for renal cell carcinoma and the effects of the tumor microenvironment on systemic therapy

Researchers explored the association between the human microbiome and improved renal cell carcinoma outcomes.

6 Feb 2023

Does the immunization order of vaccine types influence the efficacy of heterologous prime-boost vaccination, especially mRNA and protein-based vaccines?

A new study aimed to analyze whether the order of immunization of vaccine types impacted the efficacy of a heterologous prime-boost vaccination strategy.

6 Jan 2023

Using synthetic gene circuits to better control the timing of immunotherapy

In two separate studies, researchers demonstrate how synthetic biology can be used to tackle a difficult issue in cancer immunotherapy: the way immunotherapy-related approaches focused on short-term killing of tumor cells may fail to eradicate tumors because growth of tumors happens on longer timescales.

16 Dec 2022

Booster COVID-19 mRNA vaccinations marginally increase the durability of neutralizing antibody responses

Researchers investigated the immunological mechanisms behind the decreasing efficacy of COVID-19 vaccines by evaluating the durability and magnitude of neutralizing antibodies and memory B and T cell responses to booster doses of mRNA COVID-19 vaccine.

8 Dec 2022

Memory B and T cells responses differ when induced by SARS-CoV-2 infections or booster vaccinations

In a recent study published in The Journal of Immunology, a team of researchers from Japan examined the memory B and T cell responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein after the booster dose of the coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccine BNT162b2.

27 Nov 2022

Booster vaccinations in the elderly lead to impaired neutralization of SARS-CoV-2 and atypical B cells

Researchers examine neutralizing antibody responses against SARS-CoV-2 in elderly individuals who received one mRNA booster dose.

23 Oct 2022

Tumor-infiltrating lymphocytes therapy treats cancers at a large scale

A novel treatment strategy with personalized cell therapy significantly improves progression-free survival compared to standard immunotherapy in patients with advanced melanoma, according to ground-breaking results reported at the ESMO Congress 2022 from the phase 3 M14TIL trial.

12 Sep 2022

What is the association between T lymphocyte-mediated immune responses and COVID-19 severity?

Researchers examined the relationship between cell-mediated or T lymphocyte-mediated immunity and SARS-CoV-2 infection severity.

25 Aug 2022

“Drug factory” implants show promise in eradicating mesothelioma tumors

Rice University and Baylor College of Medicine researchers have shown they can eradicate advanced-stage mesothelioma tumors in mice in just a few days with a treatment combining Rice's cytokine "drug factory" implants and a checkpoint inhibitor drug.

22 Aug 2022

B-cell responses to COVID mRNA vaccine are enhanced by a 16-week interval between doses

Researchers assess the impact of extending the interval between primary and booster COVID-19 vaccine doses.

9 Aug 2022

A combined influenza and COVID-19 mRNA vaccine

A combined mRNA vaccine is capable of inducing broad and durable protection against co-infection with SARS-CoV-2 and IAV,

3 Aug 2022

Researchers compare the development and persistence of antibody and T-cell responses elicited by the mRNA BNT162b2 vaccine or SARS-CoV-2 infection

Researchers comparatively assessed the generation of B lymphocyte-mediated antibody responses and T lymphocyte-mediated cellular responses between mRNA BNT162b vaccinees and mild COVID-19 patients.

21 Jun 2022

New test can tell if you are immune to SARS-CoV-2

In a recent study published in the journal Nature Biotechnology, an international team of researchers developed and evaluated quantitative polymerase chain reaction (qPCR)-based assays to quantify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific functional T cell immunity.

15 Jun 2022

Synthetic IL-9 receptor allows T cells to fight cancer without the need for chemo or radiation

Before a patient can undergo T cell therapy designed to target cancerous tumors, the patient's entire immune system must be destroyed with chemotherapy or radiation. The toxic side effects are well known, including nausea, extreme fatigue and hair loss.

8 Jun 2022

Trial of peptide-centered SARS-CoV-2 T-cell activator in B-cell deficient individuals

A recent phase 1/2 study under review at the Nature Portfolio journal and posted to the Research Square* preprint server demonstrated that a peptide-centered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) T-cell activator, CoVac-1, was efficient in B-cell deficient people.

6 Jun 2022

SARS-CoV-2 Omicron found to be more immune evasive than other variants among mild COVID-19 convalescent patients

Researchers evaluated the humoral and T lymphocyte immune responses against SARS-CoV-2 variants of concern among mild COVID-19 convalescent patients in South Australia.

19 May 2022